ClinicalTrials.gg

Program

daprodustat

Also written as “GSK1278863”, “Daprodustat” and “Daprodustat (GSK1278863)”.

Its studies are mostly in Anemia · Diabetic Foot · Peripheral Vascular Diseases · Tendon Injuries, led by 2 companies.

Furthest: phase 3, since Jun 2, 201633 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline320 open or runningphase 3since Jun 2, 2016Jun 16, 2011none ahead
Qilu Pharmaceutical11 open or runningphase 3since Dec 10, 2025Dec 10, 2025May 2027phase 3 · NCT07300111

Also a collaborator on its studies: q2-solutions, quintiles-inc, hemocue and ppd-development-lp.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since Jun 16, 2011.

  1. Feb 11, 2016Phase 2 study in AnemiaGlaxoSmithKline · NCT02689206 · 103 enrolled · United States, Canada, Germany and more
  2. Jun 2, 2016Phase 3 study in AnemiaGlaxoSmithKline · NCT02791763 · 355 enrolled · Japan
  3. Jul 8, 2016Phase 3 study in AnemiaGlaxoSmithKline · NCT02829320 · 28 enrolled · Japan
  4. Aug 19, 20162 phase 3 studies in AnemiaGlaxoSmithKline · NCT02876835, NCT02879305
  5. Jan 20, 2017Phase 2 study in AnemiaGlaxoSmithKline · NCT03029247 · 105 enrolled · United States
  6. Jan 20, 2017Phase 3 study in AnemiaGlaxoSmithKline · NCT03029208 · 312 enrolled · United States, Argentina, Australia and more
  7. Jul 17, 20172 phase 1 studies in AnemiaGlaxoSmithKline · NCT03239522, NCT03223337
  8. Jan 8, 20182 phase 3 studies in AnemiaGlaxoSmithKline · NCT03409107, NCT03400033
  9. Feb 20, 2018Phase 2 study in AnemiaGlaxoSmithKline · NCT03446612 · 6 enrolled · United Kingdom
  10. Mar 1, 2018Phase 2 study in AnemiaGlaxoSmithKline · NCT03457701 · 15 enrolled · United States
  11. Apr 4, 2018Phase 1 study in AnemiaGlaxoSmithKline · NCT03493386 · 64 enrolled · Japan
  12. Nov 18, 2020Phase 1 study in AnemiaGlaxoSmithKline · NCT04640311 · 259 enrolled · United States
  13. Jan 4, 2023Phase 3 study in AnemiaGlaxoSmithKline · NCT05682326 · 4 enrolled · Japan, South Korea
  14. Dec 10, 2025Qilu Pharmaceutical's first study: phase 3 study in AnemiaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07300111 · 100 planned

Ahead

  1. May 2027Primary completion: phase 3 study in AnemiaQilu Pharmaceutical · NCT07300111

TargetBeta

“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
roxadustatruleAstellas Pharmaphase 447

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07300111Anemia3Not yet recruitingQilu PharmaceuticalMay 2027100
NCT05682326Anemia · Japan, South Korea3CompletedGlaxoSmithKlineOct 18, 20244
NCT04640311Anemia · United States1CompletedGlaxoSmithKlineMay 18, 2021259
NCT03493386Anemia · Japan1CompletedGlaxoSmithKlineJun 9, 201864
NCT03457701Anemia · United States2CompletedGlaxoSmithKlineJul 5, 202215
NCT03446612Anemia · United Kingdom2TerminatedGlaxoSmithKlineMay 29, 20196
NCT03409107Anemia · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineOct 7, 2020614
NCT03400033Anemia · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineJun 19, 2020407
NCT03223337Anemia · United States1CompletedGlaxoSmithKlineAug 20, 201837
NCT03239522Anemia · United Kingdom1CompletedGlaxoSmithKlineNov 28, 20176
NCT03029247Anemia · United States2CompletedGlaxoSmithKlineJul 9, 2020105
NCT03029208Anemia · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineSep 24, 2020312
NCT02879305Anemia · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineNov 9, 20202,964
NCT02876835Anemia · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineApr 19, 20213,872
NCT02829320Anemia · Japan3CompletedGlaxoSmithKlineMay 16, 201728
NCT02791763Anemia · Japan3CompletedGlaxoSmithKlineOct 26, 2018355
NCT02689206Anemia · United States, Canada, Germany and more2CompletedGlaxoSmithKlineJan 25, 2017103
NCT02371603Anemia · United States1CompletedGlaxoSmithKlineAug 12, 201570
NCT02293148Anemia · United States1CompletedGlaxoSmithKlineMar 10, 201561
NCT02231190Tendon Injuries · United States1CompletedGlaxoSmithKlineJun 12, 201526
NCT02243306Anemia · United States1CompletedGlaxoSmithKlineMay 10, 20178
NCT02075463Anemia · United States2TerminatedGlaxoSmithKlineMar 16, 201615
NCT02019719Anemia · Japan2CompletedGlaxoSmithKlineAug 6, 201497
NCT01977573Anemia · United States, Australia, Canada and more2CompletedGlaxoSmithKlineMay 1, 2015252
NCT01977482Anemia · United States, Australia, Canada and more2CompletedGlaxoSmithKlineFeb 1, 2015216
NCT01920594Surgical Procedures · United States, Canada2CompletedGlaxoSmithKlineOct 8, 201457
NCT01831804Diabetic Foot · United States1CompletedGlaxoSmithKlineFeb 10, 201765
NCT01673555Anemia · United States1CompletedGlaxoSmithKlineNov 19, 201249
NCT02135848Peripheral Vascular Diseases · United States2CompletedGlaxoSmithKlineNov 1, 201146
NCT01587924Anemia · United States, Canada, Denmark and more2CompletedGlaxoSmithKlineMay 27, 201380
NCT01587898Anemia · United States, Canada, Germany2CompletedGlaxoSmithKlineMay 7, 201372
NCT01406340Anemia · United States1TerminatedGlaxoSmithKlineAug 31, 201322
NCT01376232Anemia · India1CompletedGlaxoSmithKlineDec 20, 201023

How it is read

Names in the registry

  • “GSK1278863”, 15 entries
  • “Daprodustat”, 9 entries
  • “Daprodustat (GSK1278863)”, 2 entries
  • “Daprodustat tablets”, 1 entry
  • “1 to 4 mg tablets of GSK1278863”, 1 entry

Codes read as this program: GSK1278863.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.